Meeting
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Authors
Sinead Toomey
Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
Sinead Toomey , Alex J Eustace , Joanna Fay , Malgorzata Milewska , Ausra Teiserkiene , Elaine Kay , Darran O'Connor , Leonie S Young , Norma O'Donovan , William Grogan , Oscar S. Breathnach , Janice Maria Walshe , M. John Kennedy , Arnold D. Hill , Colm Power , Deirdre Duke , Niamh Hambly , William M. Gallagher , John Crown , Bryan Hennessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 591)
DOI
10.1200/JCO.2016.34.15_suppl.591
Abstract #
591
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Effect of somatic mutations in the four genes of the HER family on occurrence in HER2-positive breast cancer, cell proliferation rates, and resistance to HER2-targeted therapies in vitro.
First Author: Naomi Elster
Poster
2013 ASCO Annual Meeting
PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
First Author: Sibylle Loibl
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao
Poster
2016 ASCO Annual Meeting
The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy.
First Author: Alex J Eustace